Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers

Transfusion

Volumn 55, Issue 4, 2015, Pages 864-874

  Saraf, Santosh ^a   Araki, Hiroto ^a   Petro, Benjamin ^a   Park, Youngmin ^b   Taioli, Simona ^a   Yoshinaga, Kazumi G ^a   Koca, Emre ^a   Rondelli, Damiano ^a,b   Mahmud, Nadim ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UI Hospital Stem Cell Laboratory Blood and Marrow Transplant Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; HOXB4 PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PU 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; AZACITIDINE; DECITABINE; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL RENEWAL; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MOUSE; NONHUMAN; XENOTRANSPLANTATION; ADULT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD CELL; BONE MARROW CELL; CELL COUNT; CELL DIVISION; CFU COUNTING; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GRAFT SURVIVAL; IMMUNOMAGNETIC SEPARATION; NEWBORN; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SCID MOUSE; STEM CELL MOBILIZATION; XENOGRAFT;

ADULT; ANIMALS; ANTIGENS, CD34; AZACITIDINE; BLOOD CELLS; BONE MARROW CELLS; CELL COUNT; CELL DIVISION; CELLS, CULTURED; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLONY-FORMING UNITS ASSAY; CYTOKINES; DNA METHYLATION; EPIGENESIS, GENETIC; FETAL BLOOD; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROGRAFTS; HUMANS; HYDROXAMIC ACIDS; IMMUNOMAGNETIC SEPARATION; INFANT, NEWBORN; MICE; MICE, INBRED NOD; MICE, SCID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSCRIPTION, GENETIC;

EID: 84926466952     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12904     Document Type: Article

References (48)

1. Araki H, Baluchamy S, Yoshinaga K, et al. Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues. Exp Hematol 2009; 37: 1084-1095.
2. Araki H, Mahmud N, Milhem M, et al. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol 2006; 34: 140-149.
3. Araki H, Yoshinaga K, Boccuni P, et al. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 2007; 109: 3570-3578.
4. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 2004; 103: 4102-4110.
5. Center for International Blood & Marrow Transplant Research. Current uses and outcomes of hematopoietic stem cell transplantation 2012. 2012 [cited 2013 Mar 3]. Available from: http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx
6. Wang TY, Chang SJ, Chang MD, et al. Unique biological properties and application potentials of CD34+ CD38- stem cells from various sources. Taiwan J Obstet Gynecol 2009; 48: 356-369.
7. Hao QL, Shah AJ, Thiemann FT, et al. A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Blood 1995; 86: 3745-3753.
8. Wang JC, Doedens M, Dick JE,. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 1997; 89: 3919-3924.
9. Gordon MY, Blackett NM,. Some factors determining the minimum number of cells required for successful clinical engraftment. Bone Marrow Transplant 1995; 15: 659-662.
10. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939-2951.
11. Shpall EJ, Champlin R, Glaspy JA,. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
12. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
13. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-337.
14. Jantunen E, Itala M, Siitonen T, et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant 2008; 41: 239-244.
15. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-724.
16. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
17. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995; 81: 197-205.
18. Lantry LE, Zhang Z, Crist KA, et al. 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 1999; 20: 343-346.
19. Carr BI, Rahbar S, Asmeron Y, et al. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer 1988; 57: 395-402.
20. McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res 2002; 62: 4757-4766.
21. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089-7093.
22. Covey JM, D'Incalci M, Tilchen EJ, et al. Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 1986; 46: 5511-5517.
23. Schermelleh L, Haemmer A, Spada F, et al. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res 2007; 35: 4301-4312.
24. Momparler RL, Goodman J,. In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res 1977; 37: 1636-1639.
25. Jones PA, Taylor SM,. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93.
26. Halaban R, Krauthammer M, Pelizzola M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS ONE 2009; 4: e4563.
27. Saunthararajah Y, Lavelle D, DeSimone J,. DNA hypo-methylating agents and sickle cell disease. Br J Haematol 2004; 26: 629-636.
28. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001; 114: 349-357.
29. Taioli S, Petro B, Gaitonde S, et al. Evaluation of genotoxicity of chromatin modifying agents expanded hematopoietic graft in a non-human primate model [abstract]. Blood 2012; 120: 2994.
30. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.
31. Mirabello L, Savage SA, Korde L, et al. LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet 2010; 11: 77.
32. Mahmud N, Petro B, Baluchamy S, et al. Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells. Biol Blood Marrow Transplant 2014; 20: 480-489.
33. Mayani H, Lansdorp PM,. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 1994; 83: 2410-2417.
34. Danet GH, Lee HW, Luongo JL, et al. Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34(+) cells after ex vivo expansion. Exp Hematol 2001; 29: 1465-1473.
35. Dorrell C, Gan OI, Pereira DS, et al. Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood 2000; 95: 102-110.
36. Pietrobono R, Pomponi MG, Tabolacci E, et al. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 2002; 30: 3278-3285.
37. Jung M,. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001; 8: 1505-1511.
38. Bocker MT, Hellwig I, Breiling A, et al. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 2011; 117: e182-189.
39. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-236.
40. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305-2315.
41. Walasek MA, van Os R, de Haan G,. Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci 2012; 1266: 138-150.
42. Sauvageau G, Lansdorp PM, Eaves CJ, et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A 1994; 91: 12223-12227.
43. Antonchuk J, Sauvageau G, Humphries RK,. HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. Exp Hematol 2001; 29: 1125-1134.
44. Kamminga LM, Bystrykh LV, de Boer A, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006; 107: 2170-2179.
45. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221-226.
46. DeKoter RP, Singh H,. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000; 288: 1439-1441.
47. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
48. Neben S, Hellman S, Montgomery M, et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156-162.